A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: Contrast-enhanced ultrasonography and histological examination

Journal of Surgical Oncology

Volumn 107, Issue 2, 2013, Pages 155-159

  Kitamura, Hiroshi ^a   Koike, Shoichiro ^a   Nakazawa, Koh ^a   Matsumura, Hideyasu ^a   Yokoi, Kenta ^a   Nakagawa, Kan ^a   Arai, Masayuki ^a  

^a Matsumoto Hospital   (Japan)

Author keywords

anti VEGF therapy; hepatic resection; microvessel density

Indexed keywords

BEVACIZUMAB; CD34 ANTIBODY; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTRAST ENHANCEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG ADMINISTRATION SCHEDULE; FERRIC COMPOUNDS; FLUOROURACIL; HEPATECTOMY; HUMANS; IRON; LEUCOVORIN; LIVER NEOPLASMS; MICROVESSELS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; OXIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872272436     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23244     Document Type: Article

References (29)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Hochster HS, Hart LL, Ramanathan RK, et al.: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-study. Proc Am Soc Clin Oncol 2006; 24: 18s.
3. Mancuso MR, Davis R, Norberg SM, et al.: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
4. Steeghs N, Rabelink TJ, op't Roodt J, et al.: Reversiblility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2009; 21: 1100-1105.
5. Neeff HP, Drogonitz O, Klock A, et al.: Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis 2012; 27: 635-645.
6. Chun YS, Vauthey J, Boonsirikamchai P, et al.: Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-2344.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
8. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
9. Kamba T, Tam BY, Hashizume H, et al.: VEGF dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: H560-H576.
10. Baffert F, Le T, Sennino B, et al.: Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-H559.
11. Ellis LM, Curley SA, Grothey A:, Surgical resection after downsizing of colorectal metastasis in the era of bevacizumab. J Clin Oncol 2005; 23: 4853-4855.
12. Tamandl D, Gruenberger B, Klinger M, et al.: Liver resection remains a safe procedure after neoadjuvant Chemotherapy including bevacizumab: A case-controlled study. Ann Surg 2010; 252: 124-130.
13. Gruenberger B, Tamandl D, Schueller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
14. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
15. Parikh AA, Ellis LM:, Targeted therapies and surgical issues in gastrointestinal cancers. Targeted Oncol 2008; 3: 119-125.
16. Reddy SK, Morse MA, Hurwitz HI, et al.: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.
17. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007; 14: 759-765.
18. Kesmodel SB, Ellis LM, Lin E, et al.: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5260-5354.
19. Mahfud M, Breitenstein S, El-Badry AM, et al.: Impact of preoperative bevacizumab on complication s after resection of colorectal liver metastases: Case matched control study. World J Surg 2010; 34: 92-100.
20. Swisher SG, Hofstetter W, Wu TT, et al.: Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005; 241: 810-817.
21. Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23: 1237-1244.
22. Adam R, Wicherts DA, de Haas RJ, et al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality ? J Clin Oncol 2008; 26: 1635-1641.
23. Blazer DG III, Kishi Y, Maru DM, et al.: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
24. Rubbia-Brandt L, Giostra E, Brezault C, et al.: Importance of histological tumor response assessment in predicting the outcome I patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
25. Ribero D, Wang H, Donadon M, et al.: Bevecizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-2767.
26. Lehmann K, Rickenbacher A, Weber A, et al.: Chemotherapy before liver resection of colorectal metastases: Friend or Foe ? Ann Surg 2012; 255: 237-247.
27. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
28. Klinger M, Eipeldauer S, Hacker S, et al.: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35: 515-520.
29. Rubbia-Brandt L, Lauwers GY, Wang H, et al.: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430-439.